http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 06:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENDRA+Life+Sciences+Inc.++For%3A+May+27/26560636.html si-local-file:///var/storage/secattach/20260528/26560636.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENDRA+Life+Sciences+Inc.++For%3A+May+27/26560636.html Thu, 28 May 2026 06:07:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENDRA+Life+Sciences+Inc.++For%3A+May+27/26560636.html si-local-file:///var/storage/secattach/20260528/26560636.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ENDRA+Life+Sciences+Inc.++For%3A+May+27/26560636.html Thu, 28 May 2026 06:07:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26551065.html si-local-file:///var/storage/secattach/20260526/26551065.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26551065.html Tue, 26 May 2026 17:00:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26551065.html si-local-file:///var/storage/secattach/20260526/26551065.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26551065.html Tue, 26 May 2026 17:00:00 -0400 NDRA O.30741434 http://www.streetinsider.com/Earnings/ENDRA+Life+Sciences+%28NDRA%29+Misses+Q1+EPS+by+109c/26510684.html <p>ENDRA Life Sciences (NASDAQ: NDRA) reported Q1 EPS of ($1.09).</p><p>For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) <a href="http://www.streetinsider.com/ec_earnings.php?q=NDRA">click here</a>.</p> http://www.streetinsider.com/Earnings/ENDRA+Life+Sciences+%28NDRA%29+Misses+Q1+EPS+by+109c/26510684.html Mon, 18 May 2026 08:24:55 -0400 NDRA http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=0bba033d4e82b4910eb38fd882356ebe" shape="rect"><b>ENDRA Life Sciences Inc.</b></a><b> (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. </p><p> <b>Business Update</b> </p><ul class="bwlistdisc"> <li> <b>Initiated Evaluation of Strategic Alternatives</b> <ul class="bwlistcircle"> <li> On March 25, 2026, the Company announced that its Board of Directors has <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffeeds.issuerdirect.com%2Fnews-release.html%3Fnewsid%3D6842955467555002%26symbol%3DNDRA&amp;esheet=54536337&amp;newsitemid=20260518282190&amp;lan=en-US&amp;anchor=initiated+a+process+to+evaluate+strategic+alternatives+aimed+at+maximizing+shareholder+value&amp;index=2&amp;md5=a7fed90635a392cd36a24508703a9ab7" shape="rect">initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value</a>. </li> <li> ENDRA will continue to execute on its strategic and operating initiatives during the http://www.streetinsider.com/Business+Wire/ENDRA+Life+Sciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510376.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26505767.html si-local-file:///var/storage/secattach/20260515/26505767.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26505767.html Fri, 15 May 2026 16:20:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26505767.html si-local-file:///var/storage/secattach/20260515/26505767.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++ENDRA+Life+Sciences+Inc.+++++++++++++/26505767.html Fri, 15 May 2026 16:20:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+31/26504725.html si-local-file:///var/storage/secattach/20260515/26504725.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+31/26504725.html Fri, 15 May 2026 16:03:00 -0400 NDRA O.30741434 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+31/26504725.html si-local-file:///var/storage/secattach/20260515/26504725.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+31/26504725.html Fri, 15 May 2026 16:03:00 -0400 NDRA O.30741434 http://www.streetinsider.com/Corporate+News/ENDRA+Life+Sciences+reports+liver+device+validation+results/26490363.html <p>ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced multi-site clinical validation results for its TAEUS Liver device, showing correlation with MRI-PDFF measurements across 64 patients in the U.S. and Canada.</p><p>The study analyzed data from patients across independent operators and clinical sites, including an external validation site in London, Ontario. The company's thermoacoustic fat fraction measurement tracked MRI-PDFF results for patients with metabolic dysfunction-associated steatotic liver disease and those with elevated body mass index.</p><p>The validation results showed a correlation to MRI-PDFF of r=0.90 for the combined patient cohort. Diagnostic accuracy measured AUROC 0.95-0.99 at key thresholds, with a mean error of approximately http://www.streetinsider.com/Corporate+News/ENDRA+Life+Sciences+reports+liver+device+validation+results/26490363.html Thu, 14 May 2026 08:01:55 -0400 NDRA http://www.streetinsider.com/FDA/ENDRA+Life+Sciences+reports+liver+device+validation+results/26490363.html <p>ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced multi-site clinical validation results for its TAEUS Liver device, showing correlation with MRI-PDFF measurements across 64 patients in the U.S. and Canada.</p><p>The study analyzed data from patients across independent operators and clinical sites, including an external validation site in London, Ontario. The company's thermoacoustic fat fraction measurement tracked MRI-PDFF results for patients with metabolic dysfunction-associated steatotic liver disease and those with elevated body mass index.</p><p>The validation results showed a correlation to MRI-PDFF of r=0.90 for the combined patient cohort. Diagnostic accuracy measured AUROC 0.95-0.99 at key thresholds, with a mean error of approximately http://www.streetinsider.com/FDA/ENDRA+Life+Sciences+reports+liver+device+validation+results/26490363.html Thu, 14 May 2026 08:01:55 -0400 NDRA http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+Multi-Site+Validation+of+TAEUS%C2%AE+Liver+Device+Demonstrating+MRI-like+Accuracy+and+Reproducibility/26490175.html <p class="bwalignc"> <i>Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. </p><p> The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+Multi-Site+Validation+of+TAEUS%C2%AE+Liver+Device+Demonstrating+MRI-like+Accuracy+and+Reproducibility/26490175.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+Multi-Site+Validation+of+TAEUS%C2%AE+Liver+Device+Demonstrating+MRI-like+Accuracy+and+Reproducibility/26490175.html <p class="bwalignc"> <i>Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. </p><p> The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient http://www.streetinsider.com/Press+Releases/ENDRA+Life+Sciences+Reports+Multi-Site+Validation+of+TAEUS%C2%AE+Liver+Device+Demonstrating+MRI-like+Accuracy+and+Reproducibility/26490175.html Thu, 14 May 2026 08:00:00 -0400 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434